NDC product
Alogliptin and Pioglitazone
NDC 45802-351 · Padagis Israel Pharmaceuticals Ltd
Key facts
| Product NDC | 45802-351 |
|---|---|
| Proprietary name | Alogliptin and Pioglitazone |
| Nonproprietary name | Alogliptin Benzoate and Pioglitazone hydrochloride |
| Substances | ALOGLIPTIN BENZOATE, PIOGLITAZONE HYDROCHLORIDE |
| Dosage form | TABLET, FILM COATED |
| Route | ORAL |
| Labeler | Padagis Israel Pharmaceuticals Ltd |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA AUTHORIZED GENERIC |
| Application number | NDA022426 |
| Pharmacologic classes | Dipeptidyl Peptidase 4 Inhibitor [EPC], Dipeptidyl Peptidase 4 Inhibitors [MoA], Peroxisome Proliferator Receptor alpha Agonist [EPC], Peroxisome Proliferator Receptor gamma Agonist [EPC], Peroxisome Proliferator-activated Receptor alpha Agonists [MoA], Peroxisome Proliferator-activated Receptor gamma Agonists [MoA] and 2 more |
| Marketing start | Apr 8, 2016 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: